Expression Profiling of LPS Responsive miRNA in Primary Human Macrophages

Afsar Raza Naqvi1, Sheng Zhong2, Hong Dang3, Jezrom B Fordham1, Salvador Nares1, and Asma Khan2,*

1Department of Periodontics, College of Dentistry, University of Illinois at Chicago, USA
2Department of Endodontics, Center for Pain Research and Innovation, School of Dentistry, University of North Carolina, USA
3Cystic Fibrosis/Pulmonary Research and Treatment Center, Marisco Lung Institute, University of North Carolina, USA

Abstract

microRNAs (miRNAs) have emerged as important regulators of the innate and adaptive immune response. The purpose of the present study was to interrogate miRNA profiles of primary human macrophages challenged with bacterial lipopolysaccharide (LPS) with focus on expression kinetics. We employed Nanostring platform to precisely characterize the changes in miRNA expression following different doses and durations of LPS exposure. Differentially expressed miRNAs were identified in response to LPS challenge with convergent and divergent expression profiles. Pathway analysis of LPS-responsive miRNAs revealed regulation of biological processes linked to key cell signaling (including PIK3-Akt, MAP kinase, ErbB) and pathogen response pathways. Our data provide a comprehensive miRNA profiling of human primary macrophages treated with LPS. These results show that bacterial Toll like receptor (TLR) ligands can temporally modulate macrophage miRNA expression.

Keywords

microRNA; Lipopolysaccharide; Toll like receptor; Macrophages; Inflammation

Introduction

The initial immune response to bacterial infection involves the recognition of conserved pathogen-associated molecular patterns (PAMPs) such as LPS, lipoteichoic acid and peptidoglycans by pathogen recognition receptors (PRRs) including toll-like receptors (TLRs), RIG-I-like receptors and NOD-like receptors [1–3]. PRRs are expressed by a variety of cell types including macrophages (Mo), dendritic cells (DC), epithelial cells, fibroblasts and neutrophils [1,4]. Recognition of PAMPs initiates intracellular signaling

*Corresponding author: Asma A Khan, Department of Endodontics, Center for Pain Research and Innovation, School of Dentistry, University of North Carolina, USA; Tel: (919) 966 2707; asma_khan@unc.edu.
cascades which results in the expression of inflammatory mediators with the aim of eliminating the invading microbes. Most microbial pathogens contain multiple PAMPs which are recognized by different PRRs. Furthermore, the same PAMP may activate different PRRs. Thus the host immune response has the ability to coordinate both cell-type specific as well pathogen–specific responses.

The human genome encodes 10 different TLRs (TLR1–10; 4,5). TLRs differ in their cellular localization, ligand specificity and adaptor molecules. TLR 1, 2, 4, 5 and 6 are present on the cell surface while, TLR 3, 7, 8, 9, and 10 are localized on endolysosomal membranes [4]. Each TLR can recognize specific ligands that will trigger unique immune response. Some TLRs can bind wide range of ligands (both foreign and host) but others have restricted ligand specificity (either foreign or host). For instance, TLR4 can bind LPS, heat shock proteins (HSPs), polysaccharides, viral proteins, etc., while TLR3 and TLR5 specifically recognizes double stranded RNA and bacterial flagellin, respectively [1,5]. Further, TLRs also differ in their requirement of adaptor molecule for signaling.

The outcome of TLR signaling is to prime cells for immune responses. This is primarily achieved by activation/repression of a large array of genes and microRNAs (miRNAs). The discovery of miRNAs has greatly expanded our understanding of the mechanisms that regulate gene expression. miRNAs are small (18–22 nucleotides), single stranded, noncoding RNA oligonucleotides. They regulate gene expression by binding to the 3’-UTR of target messenger RNAs (mRNAs) to down-regulate gene expression at the post-transcriptional level either by translational repression or mRNA degradation [6–8]. More than 2500 miRNAs are encoded in the human genome and they regulate a wide variety of biological processes including proliferation, differentiation, cell fate determination, apoptosis, signal transduction and others [6,7]. A growing body of evidence supports the key role of miRNAs in the activation of both the innate and adaptive immune response [9–11]. Studies have shown changes in miRNA expression following LPS stimulation in various types of immune cells viz., monocytes, macrophages, etc. Several early and late LPS responsive miRNAs have been reported including miR-146, miR-155, members of let-7 family, etc. These miRNAs serve as positive and negative regulators of TLR signaling. They achieve this by targeting the components of TLR signaling pathways. For instance, miR-146 downregulates TRAF6, IRAK1 and IRAK2 while, let-7i and miR-105 target TLR4 and TLR2, respectively [12–15]. Therefore, changes in miRNA expression are not only part of host response to LPS, but also function to precisely control this response. Thus, identification of miRNA repertoire responsive to LPS challenge will be crucial in various bacterial infections.

In this report, CD14+ human macrophages were challenged with TLR4 agonist E. coli LPS, a widely accepted model to examine the innate response to microbial infection [16], and miRNAs were measured by the Nanostring nCounter platform. NanoString nCounter has been shown to be a novel, effective alternative to SYBR green real-time PCR [17,18]. It provides discrete counts of RNA transcripts and is capable of a high level of precision and sensitivity at less than one transcript copy per cell. By providing discrete counts of RNA transcripts, the nCounter overcomes the saturation limitations of microarrays while avoiding the complex sequence analysis necessitated by RNA-Seq. The data gained provides precise
and a real-time changes in miRNA copy number and is highly relevant in clinical settings as demonstrated by various studies [19,20]. Here we demonstrate that miRNA expression in primary human macrophages is altered in time and dose-dependent manner upon *E.coli* LPS challenge. These miRNAs were predicted to target important signaling pathways.

**Materials and Methods**

**Primary human macrophages culture and LPS stimulation**

Freshly prepared buffy coats were collected from healthy donors (n = 3; Sylvan N. Goldman Oklahoma Blood Institute, Oklahoma City, OK) by density gradient centrifugation, as described earlier [21–25]. Briefly, PMBCs were purified using Ficoll Paque (GE Healthcare, Piscataway, NJ) based density centrifugation. PBMCs were incubated with magnetic-labeled CD14 beads (Miltenyi Biotech, Cologne, Germany), according to manufacturer’s instructions. The purity of CD14+ cells was 95%, as determined by flow cytometry. Monocytes were plated at 2 × 10^6/ml in DMEM supplemented with penicillin (100 U/ml) and streptomycin (100 mg/ml). After 2 h, media was removed and replaced with media containing 10% FBS (Life Technologies, Grand Island, NY) and 50 ng/ml rhM-CSF (PeproTech, Rocky Hill, NJ) for Mφ differentiation. At day 7, cells were harvested, and surface expression of CD14, CD68, and HLA-DR was examined by flow cytometric analysis (data not shown). On day 7, primary Mφ were stimulated by *Escherichia coli* 055:B5 LPS (Sigma, St. Louis, MO) at 1 and 10 ng/ml and incubated for 1 and 8 hours. Controls consisted of differentiated Mφ cultured in the absence of LPS.

**Cell viability assay**

Cell viability was determined using the CellTiter 96 AQReous Cell Proliferation Assay Kit (Promega, Madison, WI) as described by Naqvi et al. [25]. Briefly, LPS treated or untreated Mφ were incubated with MTS reagent for 2 h and absorbance at 490nm were collected on a 96-well plate reader (Victor3, Perkin Elmer, Waltham, Massachusetts, USA), according to manufacturer’s instructions.

**Total RNA preparation**

At the end of the incubation period, cells were lysed and total RNA extracted using the miRNeasy Mini kit (Qiagen, Germantown, MD) according to manufacturer’s instructions. Total RNA was quantified and integrity assessed using the Nanodrop (Life Technologies) and Bioanalyzer (Agilent Technologies, Santa Clara, California, USA), respectively. All RNA samples were processed by the Genomics and Bioinformatics Core, Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill.

**nCounter miRNA expression assay**

miRNA profiling was performed using the Nanostring nCounter technology, a multiplexed, color-coded probe assay. One hundred nanograms of total RNA was used to generate cDNA libraries according to the manufacturer’s instructions. Ligation reactions, purification and dilution of probes were performed according to the manufacturer’s instructions (www.nanostring.com). Hybridization reactions were performed according to the manufacturer’s instructions with 5 ml of the five-fold diluted sample preparation reaction.
All hybridization reactions were incubated at 65°C for a minimum of 18 h. Hybridized probes were purified and counted, following the manufacturer’s instructions. All samples were processed by the Genomics and Bioinformatics Core, Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill. Data Collection was carried out in the nCounter Digital Analyzer on the nCounter Prep Station and Digital Analyzer (NanoString Technologies, Seattle, WA, USA) at the Lineberger Comprehensive Cancer Center. For each assay, a high-density scan (600 fields of view) was performed. Digital images were processed and the barcode counts were tabulated in a comma separated value (CSV) format.

Data analysis
Nanostring nCounter expression counts were inspected manually and samples with low counts throughout all probes comparable to the negative controls were identified as outliers and excluded from further analysis. The count data were normalized using the Bioconductor package, NanoStringNorm, using geometric means of low variance probes to adjust for sample content, and quantile normalization after background subtraction. The normalized expression values were log2 transformed and probes that do not have values greater than 4.587876 (or mean + 2 standard deviations of negative controls) in any of the samples were filtered out. Differential expression (DE) were analyzed by a 4-way ANOVA model with donor as random effect factor, LPS dose and time of treatment as fixed effect factors with dose and time interaction. The assay plate information was used as a surrogate for batch effect factor in the ANOVA model. Differentially expressed miRNAs were filtered at p-value < 0.05 and fold change > 1.5. DE miRNAs from different comparisons were pooled and the normalized log2 expression values were standardized across all DE miRNAs to mean of 0 and standard deviation of 1, before hierarchical clustering. The statistical analysis and clustering were performed using Partek Genomics Suite v6.6 (St. Louis, MS, USA).

Prediction of miRNA targeted pathways
For each sample set, the LPS responsive miRNAs were uploaded onto DIANA-miRPath (http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=mirpath/index) for pathway prediction. Since numerous predicted miRNA targets await validated, we selected DIANA-microT-CDS algorithm which included predicted miRNA targets.

Results
Macrophages respond to LPS by altering miRNA expression
Mφs respond to PAMPs by secreting proinflammatory cytokines that subsequently trigger both innate and adaptive arms of immunity. We first confirmed that 1ng/ml of LPS challenge is sufficient to induce secretion of proinflammatory cytokine TNFα (data not shown). We also confirmed that LPS treatment did not affect the cell viability. To examine the role of miRNAs in the early phases (1h and 8h) of LPS stimulation, we interrogated global miRNA profile in primary human Mφs. The time-kinetics of miRNA expression was analyzed by profiling 593 miRNAs using the Nanostring platform. We identified several miRNAs that were significantly altered upon LPS stimulation. Figure 1 shows a heat map of differentially expressed miRNAs across all samples. Interestingly, differentially expressed miRNAs were
predominantly downregulated across all the dose and time points examined (Figure 2A). Mφs challenged with 1ng/ml E. coli LPS for 1 hour show altered expression of 41 miRNAs; of which 5 exhibit induced expression while 36 were downregulated (Figure 2A; Table 1A). At 8h, we noted 44 differentially expressed miRNAs compared with unchallenged controls (Figure 2A, Table 1B). Among these, 6 miRNAs exhibit increased expression while 38 were downregulated. We then searched for a common set of differentially expressed miRNA, and found 11 miRNAs that were common to both the 1h and 8h time points (Figure 2B, 2C). The expression patterns of 10 of these (miR-146b, miR-193a, miR-193b, miR-218, miR-424, miR-450b-3p, miR-511, miR-573, miR-605 and miR-890) were similar at both time points. Our profiling identified previously reported LPS responsive miRNAs including miR-125b, miR-146b, miR-200, 302a, and miR-511 [21–23]. Further, we also noticed altered expression of several miRNAs that were previously not reported including newly identified miRNAs such as miR-1178, miR-1261, miR-1912 and miR-2054, etc., (Tables 1A and 1B). These results show LPS stimulation modulates Mφ miRNA profiles temporally by altering expression of different subsets of miRNAs.

Macrophages respond differentially to LPS dose

Next we compared the impact of LPS dose on Mφ miRNA profiles. To this end, Mφs were challenged with 1ng/ml and 10ng/ml of E. coli LPS and miRNA expression was monitored at 1 h and 8 h post incubation. Analysis of 1 h samples showed 41 (5 up and 36 down) differentially expressed miRNAs with a challenge dose of 1 ng/ml LPS while at 10 ng/ml we identified 15 miRNAs (4 up and 11 down) with significant change in expression (Figure 2A and Tables 1A and D). Among the differentially expressed miRNAs, 11 (miR-199a-5p, miR-218, miR-409a, miR-433, miR-511, miR-514, miR-551, miR-562, miR-556-3p, miR-1178 and miR-1205) were common to both doses (Figure 2D) and exhibited similar expression patterns (Tables 1A and C).

The impact of LPS dose was also analyzed at 8 h post incubation. In cells treated with 10 ng/ml LPS, we noticed 63 differentially expressed miRNAs among which 17 were upregulated and 46 were downregulated (Figure 2A). These results suggest that Mφ stimulated for longer time periods and with higher LPS dose exhibit significant changes in miRNAs profiles. Interestingly, we also noticed that the prolonged stimulation of Mφ induced expression of greater numbers of miRNAs at this challenge dose (63 vs 44). Comparing miRNA profiles of cells challenged with 1 and 10 ng/ml LPS for 8h we identified 28 miRNAs that were common to both doses (Figure 2E). Overall, our results indicate a correlation between miRNAs profiles and LPS dose in Mφ.

LPS responsive miRNAs are predicted to target key signaling and pathogen recognition pathways

In order to investigate the impact of altered miRNA expression on biological output, we assessed the biological pathways and predicted targets of the LPS-responsive miRNAs. The miRNAs from each dataset were subjected to pathway analysis on DIANA miRPath v3.0 (http://snf-515788.vm.okeanos.grnet.gr/dianauniverse/index.php?r=mirpath). From this we developed a list of predicted targets and biological pathways for the differentially expressed miRNAs. The list of 15 relevant pathways with significant p-values (<0.01) for each dose
and time response is provided in Table 2. Several signaling pathways namely PIK3-Akt, MAPK, ErbB, Wnt and TGF-β were highlighted. As expected, we noticed pathways involving pathogen recognition and clearance. These include endocytosis, bacterial invasion of cells and FcR-mediated phagocytosis. Polysaccharides and lipids metabolism, signaling and modification pathways were most commonly identified across all the datasets examined (Table 2A–D). These pathways are known to impact cell adhesion, motility, pathogen recognition and uptake.

Importantly, we observed a significant overlap in the pathways affected by miRNAs from different datasets indicating the role of miRNAs in polarizing the cellular responses. Nonetheless, analysis of miRNAs differentially expressed at higher LPS dose (10ng/ml) revealed pathways not shared with lower dose (1 ng/ml) challenge at similar time point. Among these are two key pathways that include phosphatidylinositol signaling system and bacterial invasion of cells. Taken together, these results show that miRNA modulation can affect various cellular processes.

**Discussion**

The innate immune response to PAMPs is associated with modulation of the host cell transcriptome. LPS from various pathogens has been demonstrated to have profound impact on gene expression. Examining the regulation of such rapid changes in gene expression is key to elucidating the underlying mechanisms. miRNAs have emerged as potent regulators of mRNA stability and translation. Studies have shown involvement of several miRNAs in LPS treatment. However, the global miRNA profiles in primary human Mφ have not been previously comprehensively examined. Here we provide updated miRNA profiling of LPS-stimulated Mφs and quantitated miRNA expression changes as a function of time and challenge dose. Our data shows that LPS challenge alters the miRNA profiles of primary human Mφ and confirms differential expression of previously described miRNAs as well as miRNAs not reported in primary Mφ using the Nanostring platform including a common set of LPS-responsive miRNAs. As our profiling included miRNAs from recent miRBase database (version 17), several novel miRNAs with potential roles in LPS signaling and/or response are identified. The role of these newly discovered miRNA is yet to be understood. Nonetheless, the changes in their expression would undoubtedly have an impact on their potential targets. Investigations on elucidating the functional role of these miRNAs in LPS treatment will uncover finer details of LPS signaling.

We observed different sets of altered miRNAs in a time and dose dependent manner. For instance, only 11 miRNAs were common to 1 h and 8 h samples when Mφ were challenged with 1 ng/ml LPS (Figure 2A) while 28 were shared between 1 ng/ml and 10 ng/ml LPS at 8 hr (Figure 2C and D). Nonetheless, our pathway analysis revealed significant overlap of pathways affected by the miRNAs. For instance, PI3K-Akt pathway was commonly targeted by miRNAs. PI3K activation is key inhibitory pathway in limiting NFκB activity and therefore checks proinflammatory cytokine (e.g. TNF-α, IL-6) production following LPS stimulation [26–29]. Several LPS responsive miRNAs target same pathway indicating regulatory fine tuning of these critical signaling pathways. Of the top 20 pathways, we noticed ~15 that were common for all the datasets. While a single miRNA can control
expression of hundreds of target mRNA, several miRNAs can also bind and cooperatively regulate expression of the same transcript [7,8]. Taken together, these observations suggest that similar cellular functions are regulated by different sets of miRNAs.

Global profiling identified several novel LPS responsive miRNAs and also confirms miRNAs that are previously demonstrated to respond and regulate LPS signaling. For instance, miRNA profiling of monocyte-derived Mφ and DCs identified miR-511 as being differentially induced [23]. Interestingly, overexpression of miR-511 was shown to increase levels of its validated target TLR4, thereby acting as positive regulator of TLR expression in DCs. In the present study, we show that miR-511 is downregulated in response to LPS and its expression varies with the dose. While miR-511 expression is ~12 fold downregulated in cells treated with 1ng/ml LPS, its expression is to ~5 folds at 10 ng/ml LPS dose. TLR4 expression is known to increase with LPS stimulation [23]. Taken together, these observations suggest that high LPS dose increases expression of miR-511 and which in turn, may contribute to elevated TLR4 levels.

We noted several miRNAs that were responsive to LPS from *E. coli* and other gram-negative bacteria including the periodontal pathogens *A. actinomycetemcomitans* and *P. gingivalis* derived LPS [21]. While *E. coli* LPS is TLR4 agonist, *A. actinomycetemcomitans* and *P. gingivalis* LPS are TLR2 and TLR2/4 agonist, respectively. This indicates that LPS signaling emanating from different TLRs converge at the activation of common set of transcription factors regulating expression of these miRNAs. Our recent findings showed that miR-24 and miR-30 regulate phagocytosis of *E. coli* by myeloid inflammatory cells [25]. Both miR-24 and members of miR-30 were downregulated in *E. coli* LPS treated Mφ and this corroborates with our findings showing reduced expression of these miRNAs in *E. coli* challenged myeloid cells. Together, these observations indicate that highly similar impact on miRNA expression by *E. coli* LPS as well as whole bacteria which will have functional implication on downstream functions. Consistent with this, we noted that LPS responsive differentially expressed miRNAs were predicted to target pathways involved in pathogen recognition and uptake.

TLR4 signaling can be activated by either MyD (MyD-dependent) or TRIF (MyD–independent) adaptor proteins. MyD-dependent signaling culminates in the activation of NFκB and MAPK (specifically p38 or JNK) which induce expression of early response genes including proinflammatory cytokines [1,2,4]. On the other hand, TRIF adaptor leads to the activation of IRF3 that induces IFN-β and interferon inducible genes. Pathway analyses of deregulated miRNAs highlight several cell signaling pathways that are integral to myeloid cell-mediated innate responses. Our *in silico* analysis highlight MAPK, Ras, Raf1 signaling to be impacted by LPS responsive miRNAs. PI3K-Akt pathway/phosphatidylinositol signaling was significantly impacted by differentially expressed miRNAs across all the datasets as predicted in our analysis. Akt-1 has been demonstrated to play key role in endotoxin tolerance [22]. This protein regulates expression of various miRNAs including let-7e and miR-181c (positively) and miR-155 and miR-125b (negatively). Let-7e controls TLR response through targeting of TLR4 while, miR-155 regulates tolerance to immune response by targeting suppressor of cytokine signaling 1 (SOCS1). Evidently, Akt −/− mice fails to exhibit endotoxin resistance suggesting the key
role of Akt pathway. This further confirms that macrophages respond to *E. coli* LPS challenge by altering expression of miRNAs that regulate both MyD-dependent and independent signaling cascades and can control signaling cascades leading to their own expression through feedback mechanisms.

Innate immunity constitutes the first line of defense by which the host recognizes and responds to invading pathogens or their conserved molecular patterns. Indeed, defective TLR signaling has been associated with plethora of pathophysiological conditions and diseases. Single nucleotide polymorphisms (SNPs) in TLR2 and TLR4 have been associated with childhood asthma, chronic obstructive pulmonary disease (COPD) and colorectal cancer [30–32]. Increased TLR4 expression leads to type 2 diabetes by reducing insulin secretion by β-cells and together with TLR2 and TLR9 contribute to the development of neurological disorders like schizophrenia and autism [32,33]. These studies highlight importance of TLRs in immune response and maintaining human physiology.

In summary, our results demonstrate that primary human macrophages respond to the TLR4 agonist, *E. coli* LPS by modulating expression of various miRNAs. These miRNA profiles are responsive to LPS dose and incubation time. In turn, these miRNAs are predicted to target key genes linked to immunity, inflammation and pain. This indicates that miRNAs play an important role in shaping innate immune responses by Mφ.

**Acknowledgments**

The authors wish to thank Dr Yan Shi and Ms Yan Li for technical support. This work was supported by the School of Dentistry, University of North Carolina-Chapel Hill, the American Association of Endodontists Foundation, and the NIH/NIDCR [R01DE021052].

**References**

1. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009; 22:240-27. Table of Contents. [PubMed: 19366914]
2. Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2012; 4
3. Bryant CE, Gay NJ, Heymans S, Sacre S5, et al. Advances in Toll-like receptor biology: Modes of activation by diverse stimuli. Crit Rev Biochem Mol Biol. 2015; 50:359–379. [PubMed: 25857820]
4. Takeda K, Akira S. Toll-like receptors. Curr. Protoc Immunol. 2015; 109:14–25. [PubMed: 25845562]
5. Gay NJ, Symmons MF, Gangloff M, Bryant CE2. Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol. 2014; 14:546–558. [PubMed: 25060580]
6. Ambros V. The functions of animal microRNAs. Nature. 2004; 431:350–355. [PubMed: 15372042]
7. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136:215–233. [PubMed: 19167326]
8. Naqvi AR, Islam MN, Choudhury NR, Haq QM. The fascinating world of RNA interference. Int J Biol Sci. 2009; 5:97–117. [PubMed: 19173032]
9. Lindsay MA. microRNAs and the immune response. Trends Immunol. 2008; 29:343–351. [PubMed: 18515182]
10. Sonkoly E, Stähle M, Pivarcsi A. MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin Cancer Biol. 2008; 18:131–140. [PubMed: 18291670]
11. Curtale G, Citarella F, Carissimi C, Goldoni M, Carucci N, et al. An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. Blood. 2010; 115:265–273. [PubMed: 19965651]

12. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006; 103:12481–12486. [PubMed: 16885212]

13. Chen XM, Splinter PL, O’Hara SP, LaRusso NF. A cellular microRNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J Biol Chem. 2007; 282:28929–28938. [PubMed: 17660297]

14. Benakanakere MR, Li Q, Eskan MA, Singh AV, Zhao J, et al. Modulation of TLR2 protein expression by miR-105 in human oral keratinocytes. J Biol Chem. 2009; 284:23107–23115. [PubMed: 19509287]

15. Sontaolalla R, Abreu MT. Innate immunity in the small intestine. Curr Opin Gastroenterol. 2012; 28:124–129. [PubMed: 22241076]

16. Payton JE, Grieselhuber NR, Chang LW, Murakami M, Geiss GK, et al. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest. 2009; 119:1714–1726. [PubMed: 19451695]

17. Malkov VA, Serikawa KA, Balantac N, Watters J, Geiss G, et al. Multiplexed measurements of gene signatures in different analyses using the Nanostring nCounter Assay System. BMC Res. 2009; 2:80.

18. Xu Z, Zhou A, Ni J, Zhang Q, Wang Y, et al. Differential expression of miRNAs and their relation to active tuberculosis. Tuberculosis (Edinb). 2015; 95:395–403. [PubMed: 25936536]

19. Costa-Reis P, Russo PA, Zhang Z, Colonna L, Maurer K. The role of miRNAs and HER2 in proliferative lupus nephritis. Arthritis Rheumatol. 2015; 67:2415–2426. [PubMed: 26016809]

20. Naqvi AR, Fordham JB, Khan A, Nares S. MicroRNAs responsive to Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis LPS modulate expression of genes regulating innate immunity in human macrophages. Innate Immun. 2014; 20:540–551. [PubMed: 24062196]

21. Androulidaki A, Iliopoulos D, Arranz A, Doxaki C, Schworer S, et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity. 2009; 31:220–231. [PubMed: 19699171]

22. Tserel L, Rummel T, Kisand K, Pihlap M, Bakhoff L. MicroRNA expression profiles of human blood monocyte-derived dendritic cells and macrophages reveal miR-511 as putative positive regulator of Toll-like receptor 4. J Biol Chem. 2011; 286:26487–26495. [PubMed: 21646346]

23. Naqvi AR, Fordham JB, Nares S. MicroRNAs responsive to Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis LPS modulate expression of genes regulating innate immunity in human macrophages. Innate Immun. 2014; 20:540–551. [PubMed: 24062196]

24. Naqvi AR, Fordham JB, Khan A, Nares S. MicroRNAs responsive to Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis LPS modulate expression of genes regulating innate immunity in human macrophages. Innate Immun. 2014; 20:540–551. [PubMed: 24062196]

25. Tengku-Muhamma TS, Hughes TR, Cryer A, Ramji DP. Synergism between lipopolysaccharide and interferon gamma in the regulation of lipoprotein lipase in macrophages. Cytokine. 1999; 11:408–415. [PubMed: 10346980]

26. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytes. J Biol Chem. 2002; 277:32124–32132. [PubMed: 12052830]

27. Luyendyk JP, Schabbauer GA, Tencati M, Holscher T, Pawlinski R. Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages. J Immunol. 2008; 180:4218–4226. [PubMed: 18322234]

28. Laird MH, Rhee SH, Perkins DJ, Medvedev AE. TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol. 2009; 85:966–977. [PubMed: 19289601]

29. Kerkhof M, Postma DS, Brunekreef B, Reijmerink NE, Wiiga AH, et al. Toll-like receptor 2 and 4 genes influence susceptibility to adverse effects of traffic-related air pollution on childhood asthma. Thorax. 2010; 65:690–697. [PubMed: 20685742]
30. Budulac SE, Boezen HM, Hiemstra PS, Lapperre TS, Vonk JM, et al. Toll-like receptor (TLR2 and TLR4) polymorphisms and chronic obstructive pulmonary disease. PLoS One. 2012; 7:e43124. [PubMed: 22952638]

31. Pimentel-Nunes P, Teixeira AL, Pereira C, Gomes M. Functional polymorphisms of Toll-like receptors 2 and 4 alter the risk for colorectal carcinoma in Europeans. Dig Liver Dis. 2013; 45:63–69. [PubMed: 22999059]

32. Ladefoged M, Buschard K, Hansen AM. Increased expression of toll-like receptor 4 and inflammatory cytokines, interleukin-6 in particular, in islets from a mouse model of obesity and type 2 diabetes. APMIS. 2013; 121:531–538. [PubMed: 23134512]

33. Enstrom AM, Onore CE, Van de Water JA, Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun. 2010; 24:64–71. [PubMed: 19666104]
Figure 1.
Heatmap showing miRNA expression in response to different doses and time points of LPS challenge. Samples are: Control#17,47,11; 1ng/ml; 1hr#1,18,22,39,43; 1ng/ml; 8hr#9,13,52,56; 10ng/ml; 1hr# 2,19,23,40,44; 10ng/ml; 8hr# 10,14,53,57.
Figure 2.
(A): Differential expression of miRNAs following LPS challenge at 1ng/ml and 10ng/ml for 1 h or 8 hours. (B–E): Common sets of differentially expressed miRNA following LPS challenge at specific doses and time points.
Table 1
List of differentially expressed miRNAs responsive to *E. coli* LPS dose and time identified in primary human macrophages.

A. Human macrophages were treated with 1ng/ml *E. coli* LPS for 1 hour.

| miRNA         | Fold change | p-value   |
|---------------|-------------|-----------|
| hsa-miR-556-3p| −31.2343    | 0.000558  |
| hsa-miR-890   | −27.2135    | 3.06E-05  |
| hsa-miR-199a-5p| −21.3307    | 0.002843  |
| hsa-miR-1204  | −13.9828    | 0.03219   |
| hsa-miR-488   | −12.1633    | 0.02769   |
| hsa-miR-511   | −11.7723    | 0.010604  |
| hsa-miR-302e  | −11.3793    | 0.00766   |
| hsa-miR-216a  | −10.741     | 0.033464  |
| hsa-miR-516b  | −10.4053    | 0.015952  |
| hsa-miR-409-3p| −10.0526    | 0.023857  |
| hsa-miR-1261  | −9.57106    | 0.009325  |
| hsa-miR-376a  | −8.6461     | 0.003217  |
| hsa-miR-33b   | −8.18745    | 0.010264  |
| hsa-miR-1253  | −7.87889    | 0.037582  |
| hsa-miR-2052  | −7.77889    | 0.045247  |
| hsa-miR-633   | −7.76623    | 0.021612  |
| hsa-miR-605   | −7.68153    | 0.029125  |
| hsa-miR-424   | −7.43781    | 0.020846  |
| hsa-miR-770-5p| −7.01844    | 0.011542  |
| hsa-miR-1205  | −6.95321    | 0.012067  |
| hsa-miR-194   | −6.89172    | 0.032392  |
| hsa-miR-569   | −6.82692    | 0.025647  |
| hsa-miR-450b-3p| −6.64106    | 0.030425  |
| hsa-miR-337-3p| −6.51625    | 0.043579  |
| hsa-miR-548j  | −6.47611    | 0.039445  |
| hsa-miR-1912  | −6.17196    | 0.032997  |
| hsa-miR-433   | −5.66386    | 0.031759  |
| hsa-miR-1271  | −5.38944    | 0.004058  |
| hsa-miR-193b  | −5.17428    | 0.045688  |
| hsa-miR-1178  | −4.85041    | 0.018656  |
| hsa-miR-146b-5p| −4.62378    | 0.046233  |
| hsa-miR-218   | −4.59623    | 0.035773  |
| hsa-miR-320a  | −3.59125    | 0.020025  |
| hsa-miR-193a-5p| −3.5568     | 0.035694  |
| hsa-miR-106a/17| −3.24695    | 0.016031  |
### A. Human macrophages were treated with 1ng/ml E.coli LPS for 1 hour.

| miRNA   | Fold change | p-value   |
|---------|-------------|-----------|
| hsa-miR-573 | −2.80172   | 0.045195  |
| hsa-miR-514 | 2.50392    | 0.047209  |
| hsa-miR-562 | 7.51529    | 0.025695  |
| hsa-miR-591 | 9.93073    | 0.026911  |
| hsa-miR-551a | 11.1935    | 0.000599  |
| hsa-miR-1296 | 17.3165    | 0.02919   |

### B. Human macrophages treated with 1 ng/ml E. coli LPS for 8 hours.

| miRNA   | Fold change | p-value   |
|---------|-------------|-----------|
| hsa-miR-193a-5p | −28.1509 | 0.000100164  |
| hsa-miR-424 | −26.3899   | 0.0018661  |
| hsa-miR-602 | −23.9685   | 0.0288658  |
| hsa-miR-186 | −23.6563   | 0.0192091  |
| hsa-miR-361-5p | −22.2274 | 0.0156237  |
| hsa-miR-218 | −21.2598   | 0.000968802 |
| hsa-miR-193b | −17.0989  | 0.00420067 |
| hsa-miR-185 | −17.0196   | 0.0349622  |
| hsa-miR-373 | −14.6641   | 0.0415649  |
| hsa-miR-605 | −14.0025   | 0.0125141  |
| hsa-miR-125b | −13.5135  | 0.0196724  |
| hsa-miR-150 | −13.2099   | 0.00240754 |
| hsa-miR-331-3p | −13.0433 | 0.00284728 |
| hsa-miR-196b | −11.6311   | 0.0415904  |
| hsa-miR-488 | −11.4972   | 0.0447984  |
| hsa-miR-151-5p | −11.2514 | 0.0110432  |
| hsa-miR-140-3p | −10.0222 | 0.0224999  |
| hsa-miR-32 | −9.82883   | 0.0413303  |
| hsa-miR-324-5p | −9.69977  | 0.00215447 |
| hsa-miR-1975 | −9.63392   | 0.00459007 |
| hsa-miR-450b-3p | −9.32785 | 0.0212821  |
| hsa-miR-511 | −9.04912   | 0.0294384  |
| hsa-miR-532-3p | −8.28998  | 0.0490303  |
| hsa-miR-615-3p | −8.2303   | 0.0262171  |
| hsa-miR-493 | −7.40798   | 0.0359485  |
| hsa-miR-890 | −6.87393   | 0.00475192 |
| hsa-miR-301a | −6.71513   | 0.0211866  |
| hsa-miR-96  | −6.65422   | 0.045645   |
| hsa-miR-146b-5p | −6.54631  | 0.0281515  |
| hsa-miR-374b | −5.29633   | 0.0186839  |
### B. Human macrophages treated with 1 ng/ml E. coli LPS for 8 hours.

| miRNA      | Fold change | p-value  |
|------------|-------------|----------|
| hsa-miR-99b| −4.58917    | 0.045494 |
| hsa-miR-345| −4.21347    | 0.0418053|
| hsa-miR-15b| −3.73893    | 0.00777077|
| hsa-miR-423-5p| −2.58407 | 0.044588 |
| hsa-miR-200c| −2.50166    | 0.0441161|
| hsa-miR-1274b| −2.14825   | 0.00956674|
| hsa-miR-221| −2.13986    | 0.00381351|
| hsa-miR-24| −1.74958    | 0.020932 |
| hsa-miR-514| 2.88047     | 0.0379482|
| hsa-miR-573| 3.10818     | 0.0438976|
| hsa-miR-518f| 3.30254     | 0.0304381|

### C. Human macrophages treated with 10ng/ml E. coli LPS for 1 hour.

| miRNA      | Fold change | p-value  |
|------------|-------------|----------|
| hsa-miR-581| −17.511     | 0.045932 |
| hsa-miR-199a-5p| −9.06846 | 0.019608 |
| hsa-miR-409-3p| −7.46168   | 0.043875 |
| hsa-miR-153| −6.914      | 0.041517 |
| hsa-miR-518c| −5.97653    | 0.025675 |
| hsa-miR-511| −5.88614    | 0.050505 |
| hsa-miR-1205| −5.26955    | 0.026363 |
| hsa-miR-556-3p| −5.16818   | 0.04638 |
| hsa-miR-433| −4.86279    | 0.046782 |
| hsa-miR-1178| −4.57924    | 0.022404 |
| hsa-miR-218| −4.09269    | 0.049502 |
| hsa-miR-514| 2.81549     | 0.028259 |
| hsa-miR-562| 9.75423     | 0.013981 |
| hsa-miR-518d-3p| 11.0995   | 0.025983 |
| hsa-miR-551a| 13.2433     | 0.000346 |

### D. Human macrophages treated with 10ng/ml E. coli LPS for 8 hour.

| miRNA      | Fold change | p-value  |
|------------|-------------|----------|
| hsa-miR-186| 0.00212131  | −95.7265 |
| hsa-miR-424| 0.000360098 | −57.373 |
| hsa-miR-29b| 0.000793683 | −45.433 |
| hsa-miR-27a| 0.0194383   | −40.4845|
| hsa-miR-32| 0.000307869 | −40.1821|
| hsa-miR-193a-5p| 4.36E-05  | −37.9784|
| hsa-miR-890| 5.02E-05    | −30.7255|
| hsa-miR-891a| 0.0294375   | −30.0668|
### D. Human macrophages treated with 10ng/ml E. coli LPS for 8 hour.

| miRNA                        | Fold change | p-value   |
|------------------------------|-------------|-----------|
| hsa-miR-193b                 | 0.00131651  | -28.6328  |
| hsa-miR-151-5p               | 0.00155507  | -26.6324  |
| hsa-miR-331-3p               | 0.000649021 | -23.0796  |
| hsa-miR-19a                  | 0.0250877   | -22.7717  |
| hsa-miR-532-3p               | 0.00728674  | -22.5814  |
| hsa-miR-185                  | 0.0238436   | -21.8341  |
| hsa-miR-18b                  | 0.0138967   | -14.7544  |
| hsa-miR-423-3p               | 0.0183292   | -13.8494  |
| hsa-miR-140-3p               | 0.0127852   | -13.1113  |
| hsa-miR-218                  | 0.005384    | -10.9014  |
| hsa-miR-574-3p               | 0.0178887   | -10.8706  |
| hsa-miR-324-5p               | 0.00167955  | -10.5147  |
| hsa-miR-520d-5p+miR-527+miR-518a-5p | 0.0332644 | -10.447   |
| hsa-miR-301a                 | 0.00822971  | -9.68532  |
| hsa-miR-605                  | 0.0270584   | -9.47062  |
| hsa-miR-516a-5p              | 0.0308221   | -9.39405  |
| hsa-miR-496                  | 0.0110786   | -9.2882   |
| hsa-miR-31                   | 0.0086838   | -9.28772  |
| hsa-miR-150                  | 0.0071677   | -8.85345  |
| hsa-miR-146b-5p              | 0.0164869   | -8.14325  |
| hsa-miR-433                  | 0.0299136   | -6.82542  |
| hsa-miR-1975                 | 0.0143885   | -6.44715  |
| hsa-miR-107                  | 0.0280177   | -5.66795  |
| hsa-miR-1205                 | 0.0420576   | -5.11632  |
| hsa-miR-106a/17              | 0.00522892  | -4.78058  |
| hsa-miR-188-5p               | 0.0445391   | -4.3485   |
| hsa-miR-374b                 | 0.0351116   | -4.29073  |
| hsa-miR-15b                  | 0.00462133  | -4.19912  |
| hsa-miR-345                  | 0.0434297   | -4.15768  |
| hsa-miR-376a                 | 0.0476912   | -4.12547  |
| hsa-miR-532-5p               | 0.027525    | -3.65767  |
| hsa-miR-509-3p               | 0.0326475   | -3.38043  |
| hsa-miR-1260                 | 0.0254564   | -2.94232  |
| hsa-miR-30e                  | 0.0451624   | -2.83118  |
| hsa-miR-22                   | 0.0228818   | -2.76943  |
| hsa-let-7a                   | 0.0243692   | -2.443    |
| hsa-miR-221                  | 0.00143387  | -2.40003  |
| hsa-miR-1274b                | 0.008082    | -2.19725  |
| hsa-miR-764                  | 0.0468539   | 3.29166   |
### Table D. Human macrophages treated with 10ng/ml E. coli LPS for 8 hour.

| miRNA     | Fold change | p-value  |
|-----------|-------------|----------|
| hsa-miR-573 | 0.0348119   | 3.31514  |
| hsa-miR-450b-5p | 0.0399014   | 3.68501  |
| hsa-miR-1180 | 0.0134275   | 3.71005  |
| hsa-miR-383 | 0.00835454  | 3.82831  |
| hsa-miR-760 | 0.0359474   | 4.69097  |
| hsa-miR-449a | 0.0445483   | 4.86847  |
| hsa-miR-759 | 0.045053    | 4.934    |
| hsa-miR-566 | 0.0181896   | 5.16446  |
| hsa-miR-2054 | 0.0210186   | 7.09867  |
| hsa-miR-432 | 0.0379926   | 7.3013   |
| hsa-miR-551a | 0.00374997  | 7.78185  |
| hsa-miR-631 | 0.0415932   | 12.3371  |
| hsa-miR-924 | 0.0284851   | 13.7512  |
| hsa-miR-644 | 0.0108704   | 17.7977  |
| hsa-miR-1323 | 0.00598167  | 21.0441  |
| hsa-miR-1915 | 0.00463882  | 21.5772  |
Table 2
List of pathways predicted to be targeted by LPS responsive miRNAs. Only top 15 pathways are mentioned.

| A. Predicted pathways of Mφ miRNAs responsive to 1ng/ml E. coli LPS challenged for 1 h. | KEGG pathway                  | p-value     | #genes | #miRNAs |
|-------------------------------------------------------------------------------------|------------------------------|-------------|--------|---------|
| Adherens junction                                                                   | 9.68E-12                     | 59          | 30     |
| Cell cycle                                                                          | 6.11E-06                     | 82          | 31     |
| TGF-beta signaling pathway                                                          | 6.67E-05                     | 51          | 30     |
| ErbB signaling pathway                                                              | 0.000115                     | 59          | 28     |
| Endocytosis                                                                         | 0.000192                     | 123         | 31     |
| Focal adhesion                                                                      | 0.000192                     | 129         | 32     |
| p53 signaling pathway                                                               | 0.000258                     | 50          | 27     |
| Rap1 signaling pathway                                                              | 0.000259                     | 127         | 30     |
| PI3K-Akt signaling pathway                                                          | 0.000521                     | 198         | 31     |
| Regulation of actin cytoskeleton                                                    | 0.002879                     | 124         | 29     |
| mTOR signaling pathway                                                              | 0.003035                     | 41          | 27     |
| AMPK signaling pathway                                                               | 0.003339                     | 78          | 29     |
| ECM-receptor interaction                                                            | 0.006131                     | 46          | 28     |
| Fc gamma R-mediated phagocytosis                                                    | 0.035122                     | 55          | 25     |
| Ras signaling pathway                                                               | 0.035122                     | 123         | 30     |

| B. Predicted pathways of Mφ miRNAs responsive to 1ng/ml E. coli LPS challenged for 8 h. | KEGG pathway                  | p-value     | #genes | #miRNAs |
|-------------------------------------------------------------------------------------|------------------------------|-------------|--------|---------|
| ErbB signaling pathway                                                              | 5.59E-06                     | 63          | 32     |
| TGF-beta signaling pathway                                                          | 5.74E-06                     | 53          | 31     |
| Endocytosis                                                                         | 2.01E-05                     | 130         | 32     |
| Ras signaling pathway                                                               | 0.000149                     | 133         | 35     |
| MAPK signaling pathway                                                               | 0.000745                     | 151         | 37     |
| Wnt signaling pathway                                                               | 0.001299                     | 86          | 33     |
| Regulation of actin cytoskeleton                                                    | 0.002783                     | 125         | 32     |
| Rap1 signaling pathway                                                              | 0.002783                     | 124         | 34     |
| Adherens junction                                                                   | 0.014892                     | 47          | 31     |
| Focal adhesion                                                                      | 0.014892                     | 117         | 33     |
| cGMP-PKG signaling pathway                                                         | 0.027851                     | 93          | 34     |
| AMPK signaling pathway                                                               | 0.027851                     | 70          | 31     |
| PI3K-Akt signaling pathway                                                          | 0.027851                     | 182         | 34     |
| SNARE interactions in vesicular transport                                            | 0.029446                     | 21          | 22     |
| p53 signaling pathway                                                               | 0.039423                     | 42          | 26     |
### C. Predicted pathways of Mφ miRNAs responsive to 10 ng/ml *E. coli* LPS challenged for 1 h.

| KEGG pathway                                                | p-value     | #genes | #miRNAs |
|-------------------------------------------------------------|-------------|--------|---------|
| AMPK signaling pathway                                      | 7.67E-05    | 42     | 10      |
| mTOR signaling pathway                                      | 0.000919    | 24     | 10      |
| Phosphatidylinositol signaling system                       | 0.001834    | 24     | 9       |
| TGF-beta signaling pathway                                 | 0.008479    | 23     | 10      |
| N-Glycan biosynthesis                                      | 0.005766    | 12     | 8       |
| Adipocytokine signaling pathway                             | 0.019586    | 22     | 9       |
| mRNA surveillance pathway                                  | 0.020065    | 28     | 11      |
| RNA degradation                                             | 0.036259    | 27     | 10      |
| Glycosylphosphatidylinositol(GPI)-anchor biosynthesis       | 0.03644     | 9      | 6       |
| Wnt signaling pathway                                       | 0.03644     | 39     | 11      |
| Gap junction                                                | 0.037595    | 21     | 11      |
| cGMP-PKG signaling pathway                                 | 0.046164    | 44     | 10      |
| Sphingolipid signaling pathway                              | 0.048088    | 31     | 10      |
| Glycosaminoglycan biosynthesis - keratan sulfate            | 0.048206    | 4      | 3       |

### D. Predicted pathways of Mφ miRNAs responsive to 10 ng/ml *E. coli* LPS challenged for 8 h.

| KEGG pathway                                                | p-value     | #genes | #miRNAs |
|-------------------------------------------------------------|-------------|--------|---------|
| ErbB signaling pathway                                      | 1.35E-07    | 73     | 44      |
| ECM-receptor interaction                                    | 4.50E-06    | 55     | 39      |
| Ras signaling pathway                                       | 9.94E-06    | 154    | 49      |
| Focal adhesion                                              | 2.26E-05    | 148    | 48      |
| Endocytosis                                                 | 6.10E-05    | 147    | 47      |
| TGF-beta signaling pathway                                 | 0.000179    | 55     | 38      |
| Mucin type O-Glycan biosynthesis                           | 0.000251    | 20     | 23      |
| Rap1 signaling pathway                                      | 0.000202    | 145    | 48      |
| Adherens junction                                           | 0.002025    | 56     | 43      |
| Wnt signaling pathway                                       | 0.000226    | 100    | 46      |
| Viral carcinogenesis                                        | 0.001341    | 118    | 47      |
| Phosphatidylinositol signaling system                       | 0.002201    | 56     | 43      |
| Bacterial invasion of epithelial cells                     | 0.002222    | 56     | 39      |
| PI3K-Akt signaling pathway                                 | 0.002786    | 217    | 48      |
| MAPK signaling pathway                                      | 0.002989    | 169    | 50      |